CPIX · XBRL financial data

Cumberland Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CPIX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	37,441	35,985	42,011	—	—	—
Revenue from contracts with customers	35,841	35,045	40,681	39,553	37,868	44,521
Cost of goods and services sold	8,653	8,811	9,119	6,067	6,586	6,667
Research and development	5,774	5,684	6,689	5,834	4,816	5,566
General and administrative	10,196	9,780	10,180	10,652	11,127	11,947
Operating income (loss)	(6,382)	(7,677)	(5,705)	(9,555)	(6,432)	(2,792)
Interest income	75	26	98	287	334	477
Interest expense	264	98	586	668	606	496
Income tax expense (benefit)	56	35	69	46	(23)	40
Net income (loss)	(3,339)	(3,508)	(5,570)	(6,279)	(6,480)	(2,836)
Earnings per share, basic USD per share	(0.22)	(0.24)	(0.38)	(0.44)	(0.46)	(0.19)
Earnings per share, diluted USD per share	(0.22)	(0.24)	(0.38)	(0.44)	(0.46)	(0.19)
Weighted average shares, basic thousands of shares	15,162	14,905	14,564	14,299	14,060	14,855
Weighted average shares, diluted thousands of shares	15,162	14,905	14,564	14,299	14,060	14,855

Fiscal years (CPIX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	24,754	27,041	19,758	18,322	17,964	11,445
Accounts receivable	12,378	6,877	13,164	9,758	11,701	16,945
Inventory	10,638	8,430	9,864	4,609	4,000	6,226
Prepaid and other current assets	2,200	3,340	3,085	3,025	2,787	2,445
Total current assets	49,970	45,688	45,870	35,714	36,452	37,060
Property and equipment, net	574	443	284	368	277	265
Right-of-use asset	2,028	1,024	5,218	6,674	6,177	8,344
Goodwill	882	882	914	914	914	914
Total assets	96,463	84,460	92,925	81,776	75,583	76,824
Accounts payable	13,396	9,641	10,819	14,038	13,914	18,568
Accrued liabilities	11,254	8,668	17,588	13,597	12,251	12,635
Current portion of long-term debt	—	—	—	0	5,100	0
Total current liabilities	25,667	19,279	28,580	27,982	31,622	36,745
Lease liability, non-current	1,060	90	4,586	5,296	4,940	4,472
Total liabilities	49,590	41,858	56,951	52,516	53,037	52,280
Accumulated deficit	(2,131)	(5,639)	(11,209)	(17,488)	(23,968)	(26,804)
Total stockholders' equity	46,991	42,814	36,266	29,603	22,853	24,880
Total liabilities and equity	96,463	84,460	92,925	81,776	75,583	76,824
Common shares outstanding (cover page) thousands of shares	14,921	14,840	14,395	14,177	13,968	14,957

Fiscal years (CPIX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(3,339)	(3,508)	(5,570)	(6,279)	(6,480)	(2,836)
Stock-based compensation	1,047	742	448	365	302	408
Depreciation and amortization	4,749	4,606	5,328	4,936	4,903	4,145
Net cash from operating activities	5,415	6,342	8,453	6,094	(612)	4,933
Purchases of property and equipment	141	104	102	281	66	98
Net cash from investing activities	(1,758)	(502)	(13,674)	(106)	58	(4,706)
Proceeds from issuing common stock	—	—	—	—	—	4,716
Share repurchases	1,852	1,387	1,053	741	579	263
Net cash from financing activities	(7,116)	(3,554)	(2,062)	(7,424)	197	(6,746)
Net change in cash	(3,459)	2,287	(7,283)	(1,436)	(357)	(6,519)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.